
The Union Health Ministry has proposed that manufacturers of antimicrobials seek approval from the central drug regulator before they can apply for a state manufacturing licence, as part of India’s response to antimicrobial resistance (AMR).
The proposal is a draft amendment, published as Gazette notification G.S.R. 983 (E) dated 6 November, to the New Drugs and Clinical Trials Rules, 2019. It would add “antimicrobials” to the definition of “new drug” in Rule 2(1)(w)(v).
What would change
Under the draft, a manufacturer would first need permission from the Central Licensing Authority (CLA) and only then apply to the State Licensing Authority for a manufacturing licence. The ministry expects this to strengthen central oversight and help ensure the quality, safety and efficacy of antimicrobial products.
Why the ministry says it is needed
The ministry cited concerns that manufacturing licences for antimicrobial products have been granted without enough scrutiny, including studies such as bioavailability/bioequivalence and stability. Without such checks, quality, safety and efficacy may suffer. Substandard or ineffective antimicrobials, it said, can help AMR develop and spread, putting patients at risk. It also noted that the G20 New Delhi Leaders’ Declaration stressed tackling AMR through a One Health approach.
How to respond
This is only a draft. The notification invites objections and suggestions from stakeholders and the public before the Central Government considers finalising it. Comments go to the Under Secretary (Drugs), Ministry of Health and Family Welfare, Kartavya Bhawan-1, New Delhi–110001, or by email to drugsdiv-mohfw[at]gov[dot]in, within 30 days from the date copies of the Gazette are made available to the public.
Source: official release by the Ministry of Health and Family Welfare, issued through the Press Information Bureau, Government of India (19 NOV 2026 10:31AM by PIB Delhi). Read the full official text: Union Health Ministry Proposes Amendment to New Drugs and Clinical Trials Rules, 2019 to Bring Antimicrobials under Central Regulatory Oversight.
How we verified this
VerifiedEvery fact, figure and quotation is taken from the official PIB release (Release ID 2338243) issued by the Ministry of Health and Family Welfare on 19 NOV 2026 10:31AM by PIB Delhi; checked against the source on publication. Story written by BDT from that release; no outside facts added.
Sources
- 1.Union Health Ministry Proposes Amendment to New Drugs and Clinical Trials Rules, 2019 to Bring Antimicrobials under Central Regulatory Oversight — Press Information Bureau, Government of India



